Origin and therapy for hypertriglyceridaemia in type 2 diabetes.

Hypertriglyceridaemia (HTG) is a risk factor for cardiovascular disease (CVD) in type 2 diabetes and is caused by the interaction of genes and non-genetic factors, specifically poor glycaemic control and obesity. In spite of statin treatment, residual risk of CVD remains high in type 2 diabetes, and this may relate to HTG and atherogenic dyslipidemia. Treatment of HTG emphasises correcting secondary factors and adverse lifestyles, in particular, diet and exercise. Pharmacotherapy is also required in most type 2 diabetic patients. Statins are the first-line therapy to achieve recommended therapeutic targets of plasma low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol. Fibrates, ezetimibe and n-3 fatty acids are adjunctive treatment options for residual and persistent HTG. Evidence for the use of niacin has been challenged by non-significant CVD outcomes in two recent large clinical trials. Further investigation is required to clarify the use of incretin-based therapies for HTG in type 2 diabetes. Extreme HTG, with risk of pancreatitis, may require insulin infusion therapy or apheresis. New therapies targeting HTG in diabetes need to be tested in clinical endpoint trials. The purpose of this review is to examine the current evidence and provide practical guidance on the management of HTG in type 2 diabetes.

• Publication year

  2014

• Venue

  World Journal of Diabetes

• Publication date

  2014-04-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.4239/wjd.v5.i2.165PMID 24748930PMCID PMC3990315
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Retraction and Republication: Primary Prevention of Cardiovascular Disease with a Mediterranean Diet. N Engl J Med 2013;368:1279-90.

  2018cited by this paper
• The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management.

  2014cited by this paper
• Hypertriglyceridemic waist phenotype is associated with decreased insulin sensitivity and incident diabetes in elderly men

  2014cited by this paper
• 2013 ACC/AHA guideline on the treatment of blood cholesterol: a fresh interpretation of old evidence.

  2014cited by this paper
• 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines

  2014cited by this paper
• Plasma phospholipid fatty acids and prostate cancer risk in the SELECT trial.

  2014cited by this paper
• 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines

  2014cited by this paper
• Relationship of lipoproteins to cardiovascular events: the AIM-HIGH Trial (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides and Impact on Global Health Outcomes).

  2013cited by this paper
• An International Atherosclerosis Society Position Paper: global recommendations for the management of dyslipidemia.

  2013cited by this paper
• Postprandial Hypertriglyceridemia and Cardiovascular Disease: Current and Future Therapies

  2013cited by this paper
• Hypertriglyceridemic Waist Might Be an Alternative to Metabolic Syndrome for Predicting Future Diabetes Mellitus

  2013cited by this paper
• Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes.

  2013cited by this paper
• Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.

  2013cited by this paper
• Severe hypertriglyceridaemia in Type 2 diabetes mellitus: beneficial effect of continuous insulin infusion.

  2013cited by this paper
• Alipogene tiparvovec: gene therapy for lipoprotein lipase deficiency

  2013cited by this paper
• Atherogenic dyslipidemia and combination pharmacotherapy in diabetes: recent clinical trials.

  2013cited by this paper
• Plasmapheresis in the management of severe hypertriglyceridemia.

  2013cited by this paper
• Primary prevention of cardiovascular disease with a Mediterranean diet.

  2013cited by this paper
• Alogliptin after acute coronary syndrome in patients with type 2 diabetes.

  2013cited by this paper
• Faculty of 1000 evaluation for Primary prevention of cardiovascular disease with a Mediterranean diet.

  2013cited by this paper
• Insulin secretion is increased in non‐diabetic subjects with fasting hypertriglyceridaemia

  2013cited by this paper
• HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment

  2013cited by this paper
• Persistent hypertriglyceridemia in statin-treated patients with type 2 diabetes mellitus

  2013cited by this paper
• n-3 fatty acids in patients with multiple cardiovascular risk factors.

  2013cited by this paper
• Poorly controlled type 2 diabetes complicated by an episode of severe hypertriglyceridaemia-induced pancreatitis

  2013cited by this paper
• Using Mendelian randomization to determine causative factors in cardiovascular disease

  2013cited by this paper
• Statin use and risk of diabetes mellitus in postmenopausal women in the Women's Health Initiative.

  2012cited by this paper
• The association of hypertriglyceridemia with cardiovascular events and pancreatitis: a systematic review and meta-analysis

  2012cited by this paper
• Clinical Practice Guideline: Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline

  2012cited by this paper
• Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial.

  2012cited by this paper
• Quantification of concordance and discordance between apolipoprotein-B and the currently recommended non-HDL-cholesterol goals for cardiovascular risk assessment in patients with diabetes and hypertriglyceridemia.

  2012cited by this paper
• Four-year follow-up after two-year dietary interventions.

  2012cited by this paper
• Treatment options for severe hypertriglyceridemia (SHTG): the role of apheresis

  2012cited by this paper
• Treatment options for the management of hypertriglyceridemia: strategies based on the best-available evidence.

  2012cited by this paper
• Effect of saxagliptin as add-on therapy in patients with poorly controlled type 2 diabetes on insulin alone or insulin combined with metformin

  2012cited by this paper
• Effects of Ethanol Intake on Lipoproteins

  2012cited by this paper
• Mutations in LPL, APOC2, APOA5, GPIHBP1 and LMF1 in patients with severe hypertriglyceridaemia

  2012cited by this paper
• Hypertriglyceridemic waist: a simple clinical phenotype associated with coronary artery disease in women.

  2012cited by this paper
• Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy

  2012cited by this paper
• Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study).

  2012cited by this paper
• Double-blind randomized clinical trial of the effects of ezetimibe on postprandial hyperlipidaemia and hyperglycaemia.

  2012cited by this paper
• n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia.

  2012cited by this paper
• Management of severe hypertriglyceridemia in the hospital: a review.

  2012cited by this paper
• A comparison of the efficacy of combined ezetimibe and statin therapy with doubling of statin dose in patients with remnant lipoproteinemia on previous statin therapy.

  2012cited by this paper
• Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis.

  2012cited by this paper
• Efficacy and long term safety of alipogene tiparvovec (AAV1-LPLS447X) gene therapy for lipoprotein lipase deficiency: an open label trial

  2012cited by this paper
• Risk of Incident Diabetes With Intensive-Dose Compared With Moderate-Dose Statin Therapy: A Meta-analysis

  2012cited by this paper
• ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).

  2011cited by this paper
• The association of hypertriglyceridemic waist phenotype with type 2 diabetes mellitus among individuals with first relative history of diabetes

  2011cited by this paper
• Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management

  2011cited by this paper
• Transcriptional Activation of Apolipoprotein CIII Expression by Glucose May Contribute to Diabetic Dyslipidemia

  2011cited by this paper
• Benefits of Modest Weight Loss in Improving Cardiovascular Risk Factors in Overweight and Obese Individuals With Type 2 Diabetes

  2011cited by this paper
• Severe hypertriglyceridemia influenced by alcohol (SHIBA).

  2011cited by this paper
• Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] trial).

  2011cited by this paper
• Meta-analysis comparing Mediterranean to low-fat diets for modification of cardiovascular risk factors.

  2011cited by this paper
• Persistent lipid abnormalities in statin‐treated patients with diabetes mellitus in Europe and Canada: results of the Dyslipidaemia International Study

  2011cited by this paper
• Standards of Medical Care in Diabetes—2012

  2011cited by this paper
• The ACCORD-Lipid study: implications for treatment of dyslipidemia in Type 2 diabetes mellitus

  2011cited by this paper
• Ezetimibe beneficially influences fasting and postprandial triglyceride-rich lipoproteins in type 2 diabetes.

  2011cited by this paper
• Genetic determinants of plasma triglycerides

  2011cited by this paper
• Effect of sitagliptin therapy on postprandial lipoprotein levels in patients with type 2 diabetes

  2011cited by this paper
• Lifestyle Intervention Leading to Moderate Weight Loss Normalizes Postprandial Triacylglycerolemia Despite Persisting Obesity

  2011cited by this paper
• Efficacy of fibrates for cardiovascular risk reduction in persons with atherogenic dyslipidemia: a meta-analysis.

  2011cited by this paper
• Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association.

  2011cited by this paper
• Effects of nutrients on postprandial lipemia.

  2011cited by this paper
• Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis.

  2011cited by this paper
• Fibrates Effect on Cardiovascular Risk Is Greater in Patients With High Triglyceride Levels or Atherogenic Dyslipidemia Profile: A Systematic Review and Meta-analysis

  2011cited by this paper
• Glucagon‐like peptide‐1‐based therapies and cardiovascular disease: looking beyond glycaemic control

  2011cited by this paper
• Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials

  2011cited by this paper
• Relation of the

  2011cited by this paper
• Implications for Treatment

  2011cited by this paper
• Effects of lifestyle interventions and long‐term weight loss on lipid outcomes – a systematic review

  2011cited by this paper
• ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).

  2011cited by this paper
• Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy.

  2011cited by this paper
• Effects of combination lipid therapy in type 2 diabetes mellitus.

  2010cited by this paper
• Usefulness of hypertriglyceridemic waist phenotype in type 2 diabetes mellitus to predict the presence of coronary artery disease as assessed by computed tomographic coronary angiography.

  2010cited by this paper
• An update on the IMProved reduction of outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) design.

  2010cited by this paper
• Selective whole blood lipoprotein apheresis to prevent pancreatitis in drug refractory hypertriglyceridemia.

  2010cited by this paper
• Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis.

  2010cited by this paper
• Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk.

  2010cited by this paper
• Cardiovascular effects of marine omega-3 fatty acids.

  2010cited by this paper
• Effects of combination lipid therapy in the management of patients with type 2 diabetes mellitus in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial.

  2010cited by this paper
• Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial.

  2010cited by this paper
• The hypertriglyceridemic-waist phenotype and the risk of coronary artery disease: results from the EPIC-Norfolk Prospective Population Study

  2010cited by this paper
• Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials.

  2010cited by this paper
• Fibrates in CVD: a step towards personalised medicine.

  2010cited by this paper
• Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis

  2010cited by this paper
• Rosuvastatin for Primary Prevention in Older Persons With Elevated C-Reactive Protein and Low to Average Low-Density Lipoprotein Cholesterol Levels: Exploratory Analysis of a Randomized Trial

  2010cited by this paper
• Smoking, inflammatory patterns and postprandial hypertriglyceridemia.

  2009cited by this paper
• Hypertriglyceridemic Waist Phenotype Predicts Increased Visceral Fat in Subjects With Type 2 Diabetes

  2009cited by this paper
• Severe hypertriglyceridemia and triglyceride apheresis

  2009cited by this paper
• Effect of Statins Alone Versus Statins Plus Ezetimibe on Carotid Atherosclerosis in Type 2 Diabetes: The SANDS (Stop Atherosclerosis in Native Diabetics Study) Trial

  2009cited by this paper
• Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Detection, Evaluation, and Treatment of High Blood Cholesterol Education Program (NCEP) Expert Panel on Executive Summary of the Third Report of the National

  2009cited by this paper
• Extended-release niacin or ezetimibe and carotid intima-media thickness.

  2009cited by this paper
• Ezetimibe monotherapy for cholesterol lowering in 2,722 people: systematic review and meta‐analysis of randomized controlled trials

  2009cited by this paper
• Plant Stanol Supplementation Decreases Serum Triacylglycerols in Subjects with Overt Hypertriglyceridemia

  2009cited by this paper
• Effect of statins alone versus statins plus ezetimibe on carotid atherosclerosis in type 2 diabetes: the SANDS (Stop Atherosclerosis in Native Diabetics Study) trial.

  2008cited by this paper
• Lipoprotein Management in Patients With Cardiometabolic Risk

  2008cited by this paper
• Apolipoprotein C-III: understanding an emerging cardiovascular risk factor.

  2008cited by this paper
• Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes.

  2008cited by this paper

• Efficacy of long‐term low carbohydrate diets for patients with type 2 diabetes: A systematic review and meta‐analysis

  2024cites this paper
• Peripheral serotonin controls dietary fat absorption and chylomicron secretion via 5-HT4 receptor in males.

  2024cites this paper
• Hyponatremia in Patients with Heart Failure beyond the Neurohormonal Activation Associated with Reduced Cardiac Output: A Holistic Approach

  2022cites this paper
• Genome-wide discovery for diabetes-dependent triglycerides-associated loci

  2022cites this paper
• Diabetic dyslipidaemia

  2021cites this paper
• Evaluation of antidiabetic effect of Cistus salviifolius L. (Cistaceae) in streptozotocin-nicotinamide induced diabetic mice

  2020cites this paper
• Role of the Gut in Diabetic Dyslipidemia

  2020cites this paper
• Endocrine diseases as causes of secondary hyperlipidemia.

  2019cites this paper
• The characteristic, antioxidative and multiple organ protective of acidic-extractable mycelium polysaccharides by Pleurotus eryngii var. tuoliensis on high-fat emulsion induced-hypertriglyceridemic mice

  2018cites this paper
• [33 Questions about Triglycerides and Cardiovascular Effects: Expert Answers].

  2017cites this paper
• Hypoglycemic and antioxidant effects of Syzygium polyanthum leaves extract on alloxan induced hyperglycemic Wistar Rats

  2017cites this paper
• Triacylglycerols: Structures and Properties

  2016cites this paper
• Cordyceps militaris Treatment Preserves Renal Function in Type 2 Diabetic Nephropathy Mice

  2016cites this paper
• Depression contributing to dyslipidemic cardiovascular risk in the metabolic syndrome

  2016cites this paper
• The Atherogenic Dyslipidemia Ratio Log (Tg)/Hdl-C Was Not Associated with Urinary Albumin Excretion Rate (Uaer) and Increased Cardiovascular Risk in Black Patients with Type 2 Diabetes

  2016cites this paper
• Hypertriglyceridemia: the importance of identifying patients at risk

  2016influential citation
• A Fast-acting Option in Severe Hypertriglycidaemia-induced Pancreatitis in an Adolescent with Type 2 Diabetes: Insulin Infusion.

  2016cites this paper
• Moderate Hypertriglyceridemia Revealed by Acute Chest Syndrome, a Milky Appearance Serum and Prior History of Recurrent Acute Pancreatitis in a Type 2 Diabetes Black Patient: A Case Report

  2016cites this paper
• Management of hypertriglyceridemia in uncontrolled type 2 diabetes mellitus patients: 2 case studies

  2016cites this paper
• Managing biological data in pathways and networks

  2015cites this paper
• Association between hypertriglyceridemia and protein oxidation and proinflammatory markers in normocholesterolemic and hypercholesterolemic individuals.

  2015cites this paper
• National trends in incidence and outcomes of acute pancreatitis among type 2 diabetics and non-diabetics in Spain (2001-2011).

  2015cites this paper
• An ontological view of cardiovascular and metabolic disease progression using genetically modified mice

  2014cites this paper
• A network biology workflow to study transcriptomics data of the diabetic liver

  2014cites this paper